ArticleFunctional & integrative genomics2026
Lipid-lowering activity of mulberry seed unsaturated fatty acids: integrating network pharmacology and experimental validation.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to gas chromatography-mass spectrometry (GC-MS) analysis, mulberry seed oil (MSO) contains a high proportion of unsaturated fatty acids, accounting for 88.26% of its total composition. Although unsaturated fatty acids are reported to have lipid-lowering activity, the molecular targets involved in the mechanism of lipid-lowering action of MSO have not yet been systematically demonstrated. This mechanism is explored through an interdisciplinary approach, employing network pharmacology and molecular docking analysis techniques, supplemented by in vivo experimental validation. We employ network pharmacology to identify candidate targets, assessed binding affinity through molecular docking, and conducted experimental validation in LO2 cells and C. elegans to evaluate lipid-lowering activity. Network pharmacology identified 157 shared targets between MSO and obesity, subsequently pinpointing IL-6 and PPARG as core targets through protein-protein interaction analysis. The active components of MSO were found to bind with these targets with high binding affinities by molecular docking. The results demonstrated that MSO alleviates lipid accumulation in oleic acid-induced LO2 cell model, reduces lowering total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), whilst simultaneously elevating high-density lipoprotein cholesterol (HDL-C) levels. Furthermore, Western blot analysis showed that MSO dose-dependently suppressed p-RAF, MEK, ERK, and BCL-2 expression, implicating the RAF/MEK/ERK pathway in MSO-mediated lipid regulation. In C. elegans, MSO lowered triglyceride and cholesterol levels and modulated the insulin/IGF-1 signaling pathway. A systemic explanation of the multi-target regulatory process of MSO over lipid metabolism is described in our findings, which is the scientific basis of its development.
Indexed as
Identifiers
42303923What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.